Your browser doesn't support javascript.
loading
Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
Sikora, Jakub; Dworski, Shaalee; Jones, E Ellen; Kamani, Mustafa A; Micsenyi, Matthew C; Sawada, Tomo; Le Faouder, Pauline; Bertrand-Michel, Justine; Dupuy, Aude; Dunn, Christopher K; Xuan, Ingrid Cong Yang; Casas, Josefina; Fabrias, Gemma; Hampson, David R; Levade, Thierry; Drake, Richard R; Medin, Jeffrey A; Walkley, Steven U.
Afiliación
  • Sikora J; Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York; Institute of Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine, Prague, Czech Republic; Institut
  • Dworski S; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Jones EE; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
  • Kamani MA; University Health Network, Toronto, Ontario, Canada.
  • Micsenyi MC; Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York.
  • Sawada T; Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York.
  • Le Faouder P; MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
  • Bertrand-Michel J; MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
  • Dupuy A; MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
  • Dunn CK; University Health Network, Toronto, Ontario, Canada.
  • Xuan ICY; Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Casas J; Research Unit on Bioactive Molecules, Department of Biomedicinal Chemistry, Institute for Advanced Chemistry of Catalonia, Spanish National Research Council, Barcelona, Spain.
  • Fabrias G; Research Unit on Bioactive Molecules, Department of Biomedicinal Chemistry, Institute for Advanced Chemistry of Catalonia, Spanish National Research Council, Barcelona, Spain.
  • Hampson DR; Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Levade T; INSERM UMR1037, Cancer Research Center of Toulouse, Universite Toulouse III Paul-Sabatier, Toulouse, France; Metabolic Biochemistry Laboratory, Federative Institute of Biology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • Drake RR; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
  • Medin JA; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: jmedin@mcw.ed
  • Walkley SU; Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: steve.walkley@einstein.yu.edu.
Am J Pathol ; 187(4): 864-883, 2017 Apr.
Article en En | MEDLINE | ID: mdl-28342444
ABSTRACT
Farber disease is a rare autosomal recessive disorder caused by acid ceramidase deficiency that usually presents as early-onset progressive visceral and neurologic disease. To understand the neurologic abnormality, we investigated behavioral, biochemical, and cellular abnormalities in the central nervous system of Asah1P361R/P361R mice, which serve as a model of Farber disease. Behaviorally, the mutant mice had reduced voluntary locomotion and exploration, increased thigmotaxis, abnormal spectra of basic behavioral activities, impaired muscle grip strength, and defects in motor coordination. A few mutant mice developed hydrocephalus. Mass spectrometry revealed elevations of ceramides, hydroxy-ceramides, dihydroceramides, sphingosine, dihexosylceramides, and monosialodihexosylganglioside in the brain. The highest accumulation was in hydroxy-ceramides. Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types (eg, neurons, endothelial cells, and choroid plexus cells), most notably microglia and/or macrophages. Coalescing and mostly perivascular granuloma-like accumulations of storage-laden CD68+ microglia and/or macrophages were seen as early as 3 weeks of age and located preferentially in white matter, periventricular zones, and meninges. Neurodegeneration was also evident in specific cerebral areas in late disease. Overall, our central nervous system studies in Asah1P361R/P361R mice substantially extend the understanding of human Farber disease and suggest that this model can be used to advance therapeutic approaches for this currently untreatable disorder.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema Nervioso Central / Lipogranulomatosis de Farber / Malformaciones del Sistema Nervioso Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Am J Pathol Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistema Nervioso Central / Lipogranulomatosis de Farber / Malformaciones del Sistema Nervioso Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Am J Pathol Año: 2017 Tipo del documento: Article